百特醫療 (BAX) 2019 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2019 年第一季財報電話會議。(接線員指示) 提醒各位,本通話由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請立即掛線。

  • I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Thanks, Candace. Good morning, and welcome to our first quarter 2019 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.

    謝謝你,Candace。各位早安,歡迎參加我們 2019 年第一季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。

  • On the call this morning, we will be discussing Baxter's first quarter 2019 financial results and our updated financial outlook for full year 2019.

    今天早上的電話會議中,我們將討論百特 2019 年第一季財務結果,以及我們更新後的 2019 全年財務展望。

  • A supplemental presentation to complement this morning's discussion can be accessed on our website.

    可在我們網站上取得補充簡報,以配合今天早上的討論。

  • This presentation, along with related non-GAAP reconciliations, can be accessed on Baxter's external website in the Investors section under Events and News.

    此簡報以及相關的非 GAAP 調節表,可於百特對外網站的「投資人」專區中「活動與新聞」項下查閱。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters, contain forward-looking statements that involve risks and uncertainties.

    接下來,在開始我們的準備發言前,先提醒各位,本簡報(包括關於我們財務展望、新產品開發、業務開發及法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。

  • And of course, our actual results could differ materially from our current expectations.

    當然,我們的實際結果可能與目前的預期有重大差異。

  • Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.

    有關可能導致實際結果與預期有重大差異之因素的更多細節,請參閱今日新聞稿及我們向 SEC 提交的文件。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。

  • A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and is available on our website.

    今日所討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標的調節表,已包含在我們今早發布的財報新聞稿中,並可於我們網站取得。

  • On the call this morning, we will be discussing operational sales growth, which adjusts for the impact of foreign exchange and generic competition for cyclophosphamide in the U.S.

    今天早上的電話會議中,我們將討論營運銷售成長(operational sales growth),其已調整外匯影響以及美國市場環磷醯胺(cyclophosphamide)之學名藥競爭影響。

  • With that, I'd now like to turn the call over to Joe. Joe?

    接下來,我想把電話交給 Joe。Joe?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Good morning, and thank you for joining us. We're pleased to share our first quarter results with you today and to discuss our updated expectations for 2019. I will begin with a quick review of our performance in the quarter, and Jay will then provide more detail on the financials. We will wrap up with Q&A.

    各位早安,感謝各位加入我們。我們很高興今天與各位分享第一季業績,並討論我們更新後的 2019 年預期。我將先快速回顧本季表現,接著 Jay 會提供更詳細的財務說明。最後我們將進行問答。

  • Baxter opened 2019 with a solid first quarter, delivering sales growth of 2% from both a constant currency and operational basis, representing the high end of our projections. Reported sales declined 2% with foreign exchange negatively impacting sales by approximately 400 basis points in the quarter.

    百特以穩健的第一季揭開 2019 年序幕,以固定匯率與營運基礎計算的銷售成長皆為 2%,達到我們預測區間的高端。受外匯影響,本季報告銷售額下滑 2%,外匯對銷售造成約 400 個基點的負面影響。

  • On the bottom line, adjusted earnings per share were $0.76 and advancing 9% year-over-year. Growth was driven by top line sales performance, operational efficiency initiatives, a lower tax rate and a reduced share count. The breadth and essential nature of our portfolio reinforced Baxter's underlying stability even in a dynamic health care landscape.

    在獲利方面,調整後每股盈餘為 0.76 美元,年增 9%。成長動能來自營收端銷售表現、營運效率提升措施、較低的稅率以及股數減少。我們產品組合的廣度與其不可或缺的特性,即使在多變的醫療照護環境中,也強化了百特的基本穩定性。

  • First quarter results benefited from positive performance across our Renal Care, Pharmaceuticals, Advanced Surgery and Acute Therapies' businesses, supplemented by increased demand for Baxter's cytotoxic contract manufacturing services. This strength helped offset the sales declines in our Medication Delivery and Nutrition businesses in the quarter as expected.

    第一季業績受惠於腎臟照護、製藥、先進外科與急性療法等業務的正向表現,並由百特細胞毒性藥物委託製造服務需求增加所補強。這股強勁表現如預期抵銷了本季藥物輸注與營養業務的銷售下滑。

  • Renal Care continued to perform well and maintained underlying momentum globally. Negative growth in the U.S. as expected was due to our strategic exit of the in-center hemodialysis bloodline business. Demand for our peritoneal dialysis therapies remains strong with patient volumes increasing high single digits in the U.S. and mid-single digits globally. The continuing rollout of our new PD cyclers, AMIA in North America, KAGUYA in Japan and CLARIA in Europe is helping to fuel this growth.

    腎臟照護持續表現良好,並在全球維持基本動能。美國市場如預期出現負成長,原因是我們策略性退出院內血液透析血路(bloodline)業務。我們腹膜透析(PD)治療需求仍然強勁,美國病患量以高個位數成長,全球則以中個位數成長。我們新一代 PD 透析機的持續推廣——北美的 AMIA、日本的 KAGUYA,以及歐洲的 CLARIA——正協助推動此成長。

  • Pharmaceuticals delivered a strong mid-single-digit growth globally on a constant currency basis despite facing unfavorable comparisons from increased U.S. generic competition for cyclophosphamide and BREVIBLOC. The strength in the Pharmaceuticals business reflects the positive contribution of the Claris Injectables portfolio and our steady launch of new molecules, including the recent launches of 2 premixes in the U.S., dexmed and epti. Increased demand for Baxter's Hospital pharmacy compounding services as well as growth in our anesthesia business also contributed to growth in the quarter.

    製藥業務在固定匯率基礎下,全球實現強勁的中個位數成長,儘管面臨不利比較基期:美國市場環磷醯胺與 BREVIBLOC 的學名藥競爭加劇。製藥業務的強勁表現反映 Claris Injectables 產品組合的正面貢獻,以及我們穩定推出新分子產品,包括近期在美國上市的兩款預混製劑(premixes)dexmed 與 epti。此外,百特醫院藥局調配(compounding)服務需求增加,以及麻醉業務成長,也共同帶動本季成長。

  • Double-digit constant currency growth in Advanced Surgery was driven by the U.S., which benefited from last year's acquisition of RECOTHROM and PREVELEAK. We're continuing to enhance our hemostatic product line in response to customer needs, most recently with the FDA approval of a next-generation faster prep configuration for FLOSEAL. This makes it even easier and quicker to employ our leading hemostatic in the operating room.

    先進外科在固定匯率基礎下實現雙位數成長,主要由美國市場帶動,受惠於去年收購 RECOTHROM 與 PREVELEAK。我們持續因應客戶需求強化止血產品線,最近的進展是 FLOSEAL 獲得 FDA 核准下一代、更快速備製(faster prep)的配置。這讓我們在手術室中使用領先的止血產品變得更容易、更快速。

  • And our Acute Therapies business delivered solid mid-single-digit constant currency growth globally. Recall last year, this business benefited from an intense flu season, creating a difficult year-over-year comparison. We continue to see strong trajectory here with the launch of our next-generation PrisMAX technology, gaining traction in the ICUs in Europe and is off Q1 Asia Pacific as well.

    我們的急性療法業務在固定匯率基礎下,全球實現穩健的中個位數成長。回顧去年,該業務受惠於嚴重流感季,造成較高的比較基期,使年對年比較更具挑戰。我們仍持續看到強勁的成長軌跡;我們下一代 PrisMAX 技術的推出正在歐洲加護病房(ICU)獲得採用並逐步擴大,且在亞太地區第一季也有良好開局。

  • This quarter, Baxter and NantHealth also announced that a digital health solution is now available to connect Prismaflex with the hospital EMR system. This represents a key enhancement in our digital care portfolio.

    本季,百特與 NantHealth 亦宣布,一項數位健康解決方案現已可用,能將 Prismaflex 與醫院 EMR 系統連結。這代表我們數位照護產品組合的一項關鍵強化。

  • In addition, a new collaboration with bioMérieux is focused on identifying biomarkers to diagnose acute kidney injury earlier, reflecting our strategy to broaden our impact across the continuum of care. The growth in this business was partially offset by the anticipated declines in our Medication Delivery and Nutrition businesses. This past quarter, Medication Delivery faced a challenging comparison to our first quarter 2018.

    此外,與 bioMérieux 的新合作聚焦於辨識生物標記(biomarkers),以更早診斷急性腎損傷,反映我們擴大在整體照護連續體中影響力的策略。該業務的成長部分被我們藥物輸注與營養業務如預期的下滑所抵銷。在上一季,藥物輸注業務面臨與 2018 年第一季相比的艱難比較基期。

  • You will recall the demand for U.S. large-volume IV solutions spiked in the first half of last year. This was due to hospitals and distributors stocking up in response to industry-wide supply challenges following Hurricane Maria as well as the intense flu season. Performance in this business is expected to improve sequentially over the course of 2019 driven in part by our ongoing recapture efforts for small volume parenterals and the continued uptake of our new pump platforms Spectrum IQ in North America and Evo IQ in selected international markets.

    各位會記得,美國大容量靜脈輸液(IV solutions)的需求在去年上半年激增。這是因為在瑪麗亞颶風後產業供應普遍吃緊,加上嚴重流感季,醫院與經銷商為因應而提前備貨。預期該業務表現將在 2019 年期間逐季改善,部分動能來自我們持續回收小容量注射劑(small volume parenterals)市占的努力,以及我們新一代輸注幫浦平台在北美的 Spectrum IQ 與在部分國際市場的 Evo IQ 持續導入與採用。

  • And as I have mentioned previously, we are re-basing our Nutrition business in the U.S. The upcoming launch of Clinolipid marks our first U.S. launch in our Nutrition business in over a decade. It will be an important milestone in our efforts to reactivate growth.

    如我先前提到的,我們正在美國重新奠定我們的營養業務基礎。Clinolipid 即將上市,標誌著我們營養業務在十多年來首次於美國推出新產品。這將是我們重啟成長努力中的一個重要里程碑。

  • Our employee base remains highly engaged and focused on delivering innovation that improves patient outcomes, enhances safety, facilitates the shift of care to the home setting and increases the ready access to generics, including drugs in short supply. This will allow us to address many of the pressing issues facing hospitals today as they look for opportunities to further reduce the potential for medication error and decrease costs.

    我們的員工隊伍仍保持高度投入,並專注於提供能改善病患治療結果、提升安全性、促進照護轉向居家場域,以及增加學名藥(包括短缺藥品)可近性的創新。這將使我們得以因應當前醫院面臨的多項迫切議題,因為醫院正尋求進一步降低用藥錯誤風險並降低成本的機會。

  • In summary, we're encouraged by the underlying strength of the quarter. Our results are built on a combination of enhanced operational efficiency and a revitalized innovation pipeline as we are well positioned for growth acceleration.

    總結而言,我們對本季的基本面強勁感到鼓舞。我們的成果建立在營運效率提升與創新管線重振的結合之上,使我們具備加速成長的良好定位。

  • Before I pass it over to Jay, I want to provide a quick update on our quality efforts. As you know, we have been operating since 2013 with an FDA warning letter in place for our North Carolina and Jayuya, Puerto Rico manufacturing plants. This week, we received notice that the FDA has now classified our Jayuya site as voluntary action indicated or VAI. We're pleased with this development, which we believe reflects our steadfast commitment to quality in Baxter and acknowledges progress in our efforts to help ensure reliable product supply for our customers.

    在我把時間交給 Jay 之前,我想就我們的品質工作提供一個簡要更新。如各位所知,自 2013 年以來,我們北卡羅來納州與波多黎各 Jayuya 的製造廠一直在 FDA 警告信的狀態下運作。本週,我們收到通知,FDA 現已將我們的 Jayuya 廠區分類為「建議自願行動」(voluntary action indicated,VAI)。我們對此進展感到欣慰;我們相信這反映了 Baxter 對品質一貫且堅定的承諾,也肯定了我們在協助確保為客戶提供可靠產品供應方面所取得的進展。

  • Now I will pass it to Jay to provide more details on our financial performance and outlook.

    現在我將把時間交給 Jay,請他就我們的財務表現與展望提供更多細節。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Thanks, Joe, and good morning, everyone. As Joe mentioned, our first quarter results, which exceeded our expectations, position us well for accelerating growth throughout the year. I'll start by discussing our first quarter results before providing our updated financial outlook for 2019.

    謝謝你,Joe,各位早安。如 Joe 所提到的,我們第一季的結果超出預期,使我們在全年加速成長方面處於有利位置。我將先說明第一季的結果,接著提供我們更新後的 2019 年財務展望。

  • Beginning with the first quarter, global sales of $2.6 billion decreased 2% on a reported basis but increased 2% on both a constant currency and operational basis, reflecting global strength across several of our businesses. On the bottom line, adjusted earnings increased 9% to $0.76 per diluted share. This exceeded our guidance of $0.66 to $0.68 per share driven by solid operational performance, phasing of certain R&D investments and a lower tax rate.

    先從第一季開始,全球銷售額為 26 億美元,以報告基礎計下降 2%,但以固定匯率與營運基礎計皆成長 2%,反映我們多項業務在全球的強勁表現。在獲利方面,調整後盈餘成長 9%,至每股稀釋後 0.76 美元。此結果高於我們每股 0.66 至 0.68 美元的指引,主要受惠於穩健的營運表現、部分研發投資時點的安排,以及較低的稅率。

  • Now I'll walk you through performance by our geographic segments and global businesses. Note for this quarter, constant currency growth is equal to operational sales growth for all businesses and segments except for our Pharmaceuticals business in the Americas region, for which we will provide operational growth in addition to constant currency growth.

    接下來我將帶各位檢視我們各地理區隔與全球業務的表現。請注意,本季除美洲地區的製藥業務外,所有業務與區隔的固定匯率成長皆等同於營運銷售成長;針對美洲地區的製藥業務,我們將在提供固定匯率成長之外,另行提供營運成長。

  • Starting first with sales growth for our 3 geographic segments. Sales in the Americas declined 1% on a constant currency basis and were flat operationally. Sales in Europe, Middle East and Africa grew 4% on a constant currency basis, and sales in our Asia Pacific region advanced 7% on a constant currency basis.

    先從我們三個地理區隔的銷售成長談起。美洲地區銷售以固定匯率計下降 1%,以營運基礎計持平。歐洲、中東與非洲地區以固定匯率計成長 4%,而亞太地區以固定匯率計成長 7%。

  • Moving on to performance by global businesses. Global sales for Renal Care were $851 million, advancing 3% on a constant currency basis. Performance in the quarter was driven by continued momentum for PD therapies partially offset by lower sales in the U.S. for select in-center HD products, including the recently exited bloodline business. Adjusting for this impact, underlying growth in the Renal Care business was approximately 6% in the U.S. and 5% globally.

    接著看各全球業務的表現。腎臟照護(Renal Care)全球銷售額為 8.51 億美元,以固定匯率計成長 3%。本季表現主要由腹膜透析(PD)療法的持續動能所帶動,但部分被美國特定院內血液透析(HD)產品銷售下滑所抵銷,其中包括近期已退出的血路(bloodline)業務。若排除此影響,腎臟照護業務的內生成長在美國約為 6%,全球約為 5%。

  • Sales in Medication Delivery of $634 million declined 4% on a constant currency basis, in line with our expectations. We are on track with our recapture efforts related to small-volume parenterals as our teams continue to reinforce to our customers the safety and efficiency of our SVPs for drug reconstitution.

    用藥輸送(Medication Delivery)銷售額為 6.34 億美元,以固定匯率計下降 4%,符合我們的預期。我們與小容量注射劑(SVP)相關的回收(recapture)工作正按計畫推進,團隊持續向客戶強調我們 SVP 在藥品復溶方面的安全性與效率。

  • Finally, we are pleased with the market response to both our Spectrum IQ and Evo IQ infusion pumps. As Joe mentioned, we expect growth to accelerate in this business over the course of the year as we anniversary the 1H 2018 stocking impact, execute on SVP recapture efforts, capitalize on new pump launches and improve product availability internationally.

    最後,我們對市場對 Spectrum IQ 與 Evo IQ 輸注幫浦的反應感到滿意。如 Joe 所提到的,隨著我們度過 2018 年上半年備貨影響的比較基期、執行 SVP 回收工作、把握新幫浦上市機會,並改善國際市場的產品供應,我們預期該業務在今年將逐步加速成長。

  • Pharmaceutical sales were $509 million, increasing 6% constant currency and 9% operationally. Contributing to performance in the quarter was strength in our international hospital pharmacy compounding business, increasing demand for anesthesia and critical care products and robust sales of generic injectable drugs, which benefited from the new product launches Joe discussed earlier. Pharmaceutical growth in the quarter was partially offset by approximately $40 million of lower U.S. sales of BREVIBLOC and cyclo as compared to the prior year period.

    製藥(Pharmaceutical)銷售額為 5.09 億美元,以固定匯率計成長 6%,以營運基礎計成長 9%。本季表現的貢獻因素包括:我們國際院內藥局調配(compounding)業務的強勁表現、麻醉與重症照護產品需求增加,以及學名注射劑的強勁銷售,後者受惠於 Joe 先前提到的新產品上市。本季製藥成長部分被美國 BREVIBLOC 與 cyclo 銷售較去年同期減少約 4,000 萬美元所抵銷。

  • Moving to Nutrition. Total sales were $205 million, down 5% on a constant currency basis. We continue to focus on returning to positive growth in the U.S. and are gaining traction with our recapture efforts. International sales also declined in the quarter primarily driven by the phasing of some orders in Asia Pacific and CEMEA, which shifted from Q1 to later in the year. We remain focused on enhancing performance for our global Nutrition business through improved execution and innovation, including the introduction of new products for both U.S. and international markets. We expect sequential improvement in growth rates for our Nutrition business throughout 2019.

    接著談營養(Nutrition)。總銷售額為 2.05 億美元,以固定匯率計下降 5%。我們持續聚焦於讓美國市場回到正成長,且我們的回收工作正逐步取得進展。國際銷售本季亦下滑,主要因亞太與 CEMEA 地區部分訂單的時點安排,從第一季延後至今年稍晚。我們仍專注於透過更佳的執行力與創新來提升全球營養業務表現,包括為美國與國際市場導入新產品。我們預期 2019 年營養業務的成長率將逐季改善。

  • Sales of $198 million in Advanced Surgery increased 12% on a constant currency basis. Growth in the quarter was driven by increased sales of hemostats and sealants, including a contribution from RECOTHROM and PREVELEAK of approximately $17 million in the quarter. The acquisition of these assets from Mallinckrodt has allowed us to broaden our portfolio of hemostats and sealants, so we can offer surgeons more choices.

    先進外科(Advanced Surgery)銷售額為 1.98 億美元,以固定匯率計成長 12%。本季成長由止血劑與封合劑銷售增加所帶動,其中 RECOTHROM 與 PREVELEAK 本季合計貢獻約 1,700 萬美元。自 Mallinckrodt 收購這些資產,使我們得以擴充止血劑與封合劑產品組合,從而為外科醫師提供更多選擇。

  • Sales in our Acute Therapies business were $128 million, representing growth of 4% on a constant currency basis. As Joe mentioned, this business faced a challenging year-over-year comparison as Q1 2018 benefited by approximately $11 million due to flu-related sales in the quarter. Adjusting for this impact, growth in our acute business remains strong driven by new product launches, continued focus on geographic expansion and our clinical education efforts, demonstrating the benefits of CRRT for the treatment of hemodynamically unstable AKI patients.

    急性治療(Acute Therapies)業務銷售額為 1.28 億美元,以固定匯率計成長 4%。如 Joe 所提到的,該業務面臨較具挑戰性的年對年比較,因為 2018 年第一季受流感相關銷售帶動,約增加 1,100 萬美元。若排除此影響,我們急性治療業務的成長仍然強勁,主要由新產品上市、持續聚焦地理擴張,以及我們的臨床教育工作所驅動,並展現連續性腎臟替代治療(CRRT)在治療血流動力學不穩定之急性腎損傷(AKI)患者方面的效益。

  • Finally, sales in our other category, which primarily includes our contract manufacturing services, were $107 million, an increase of 8% on a constant currency basis. Performance in the quarter was primarily driven by increased demand for our cytotoxic contract manufacturing services and reflects an easier comparison to the prior year period.

    最後,我們其他類別的銷售額(主要包括我們的合約製造服務)為1.07億美元,按固定匯率計算成長8%。本季表現主要受我們細胞毒性合約製造服務需求增加所帶動,並反映與去年同期相比基期較為有利。

  • Moving through the rest of the P&L. Our adjusted gross margin of 43.7% declined slightly as compared to the prior year period as the benefits from manufacturing improvements and portfolio optimization initiatives were more than offset by lower U.S. sales of cyclo and BREVIBLOC and a less favorable product mix. Adjusted SG&A totaled $587 million, flat to prior year on a reported basis and increasing 4% on a constant currency basis. The positive contribution from our targeted initiatives to improve operational efficiency were partially offset by the loss of approximately $7 million in transition service income received from Shire in 2018. In addition, as we continue to ramp up our efforts on accelerating innovation, we are making select investments in sales and marketing to help ensure successful commercial execution of new product launches.

    接著看損益表其餘項目。我們的調整後毛利率為43.7%,較去年同期小幅下滑;製造改善與產品組合優化計畫帶來的效益,已被美國cyclo與BREVIBLOC銷售下滑以及較不利的產品組合所抵銷。調整後銷售、一般及行政費用(SG&A)合計5.87億美元,按報告基礎與去年持平,按固定匯率計算成長4%。我們為提升營運效率所推動的重點計畫帶來的正面貢獻,部分被2018年自Shire取得、約700萬美元的過渡服務收入消失所抵銷。此外,隨著我們持續加速創新,我們也在銷售與行銷方面進行選擇性投資,以協助確保新產品上市的商業化執行成功。

  • Adjusted R&D spending in the quarter of $114 million decreased 17% on a reported basis and 13% on a constant currency basis versus the prior year period. R&D expenses in the quarter were impacted by the timing of certain project-related spend, which is expected to pick up beginning in the second quarter.

    本季調整後研發(R&D)支出為1.14億美元,較去年同期按報告基礎下降17%,按固定匯率計算下降13%。本季研發費用受到部分專案相關支出時點的影響,預期自第二季起將回升。

  • We continue to prioritize strategic investments in our innovation pipeline and the phasing of this trend does not materially impact any of our time lines related to new product launches.

    我們仍優先投入創新管線的策略性投資,而此趨勢的分期安排不會對任何與新產品上市相關的時程造成重大影響。

  • Adjusted operating margin in the quarter was 17.1%, an increase of 40 basis points versus the prior year. Net interest expense totaled $18 million in the first quarter, an increase of $6 million compared to the prior year driven by a lower interest income and an increase in commercial paper balances in the quarter.

    本季調整後營業利益率為17.1%,較去年同期增加40個基點。第一季淨利息費用合計1,800萬美元,較去年增加600萬美元,主要因利息收入較低,以及本季商業本票餘額增加所致。

  • Adjusted other income totaled $25 million in the quarter driven by pension benefits and a gain on an equity investment as well as foreign exchange gains on balance sheet positions. The adjusted tax rate was 12.7% for the quarter, favorable to our expectations primarily driven by a benefit of $34 million related to stock compensation deductions as compared to $13 million in deductions the previous year.

    本季調整後其他收益合計2,500萬美元,主要來自退休金利益、股權投資處分收益,以及資產負債表部位的外匯收益。本季調整後有效稅率為12.7%,優於我們預期,主要因與股票薪酬扣除相關的稅務利益為3,400萬美元,而去年同期扣除為1,300萬美元。

  • And as previously mentioned, adjusted earnings of $0.76 per diluted share exceeded our guidance of $0.66 to $0.68 per share. Within the first quarter, we repurchased approximately $600 million or 8 million shares of Baxter stock, which was partially offset by option-related dilution in the quarter.

    此外,如先前所提,調整後每股稀釋盈餘0.76美元,高於我們每股0.66至0.68美元的指引。第一季內,我們回購約6億美元、約800萬股的Baxter股票,但部分被本季與選擇權相關的稀釋所抵銷。

  • Before turning to the 2019 outlook, I will provide some commentary regarding cash flow performance. In the first quarter, free cash flow of negative $50 million was in line of with our expectations due largely to normal seasonality of the business. We do expect improvement throughout the year, particularly with respect to days inventory on hand.

    在談2019年展望之前,我先就現金流表現提供一些說明。第一季自由現金流為負5,000萬美元,符合我們預期,主要是因業務正常季節性所致。我們預期全年將逐步改善,尤其是在庫存持有天數方面。

  • Let me conclude my comments this morning by providing our guidance for the full year 2019 and the second quarter. For the full year 2019, we continue to expect flat to 1% reported sales growth globally, 2% to 3% constant currency growth and 3% to 4% operational growth.

    最後,我以提供我們2019年全年與第二季的指引作為今天上午的結語。就2019年全年而言,我們仍預期全球報告口徑銷售成長持平至1%,固定匯率成長2%至3%,營運成長3%至4%。

  • Moving to full year guidance by business on a constant currency basis except where otherwise noted. In Renal Care, we continue to expect growth of 2% to 3% with ongoing momentum in PD being partially offset by lower sales in U.S. in-center HD. As a reminder, the strategic exits made in this business are expected to negatively impact Renal Care sales in 2019 by approximately $55 million.

    接著按業務別說明全年指引(除非另有註明,均以固定匯率為基礎)。在腎臟照護(Renal Care)方面,我們仍預期成長2%至3%,其中腹膜透析(PD)的持續動能,將部分被美國院內血液透析(in-center HD)銷售下滑所抵銷。提醒一下,該業務的策略性退出預期將在2019年對腎臟照護銷售造成約5,500萬美元的負面影響。

  • In Medication Delivery, we continue to expect sales to increase approximately 6% with sequential improvement due to the drivers referenced earlier.

    在藥物輸送(Medication Delivery)方面,我們仍預期銷售約成長6%,並將因先前提及的驅動因素而呈現逐季改善。

  • For our Pharmaceuticals business, we now expect a decline of low single digits on a constant currency basis. U.S. cyclo sales are now expected to total approximately $105 million versus our previous assumption of $95 million. Adjusting for U.S. cyclo, operational growth is expected to increase low single digits. As a reminder, BREVIBLOC sales are included in operational growth and are expected to decline approximately $75 million in 2019.

    在製藥(Pharmaceuticals)業務方面,我們目前預期按固定匯率計算將小幅下滑(低個位數)。美國cyclo銷售目前預期約為1.05億美元,高於我們先前假設的9,500萬美元。若排除美國cyclo,營運成長預期將為低個位數成長。提醒一下,BREVIBLOC銷售已納入營運成長中,且預期2019年將下滑約7,500萬美元。

  • Moving to Clinical Nutrition, we continue to expect sales growth of approximately 3%. For our Advanced Surgery business, we continue to expect sales to increase 3% to 4% on a constant currency basis.

    在臨床營養(Clinical Nutrition)方面,我們仍預期銷售成長約3%。在先進外科(Advanced Surgery)業務方面,我們仍預期按固定匯率計算銷售成長3%至4%。

  • For the Acute Therapies business, we continue to expect growth of approximately 7% to 8%. Finally, in our other business, we now expect sales to decline low to mid-single digits.

    在急性治療(Acute Therapies)業務方面,我們仍預期成長約7%至8%。最後,在其他業務方面,我們目前預期銷售將下滑低至中個位數。

  • Moving down to P&L. We now anticipate adjusted operating margin expansion of 80 to 100 basis points. We now expect net interest expense of approximately $65 million to $70 million and adjusted other income of approximately $85 million for 2019.

    接著往下看損益表。我們目前預期調整後營業利益率將擴張80至100個基點。我們目前預期2019年淨利息費用約為6,500萬至7,000萬美元,調整後其他收益約為8,500萬美元。

  • For the year, we now expect an adjusted tax rate of approximately 17%, reflecting the favorability from Q1. We now anticipate a slightly higher full year diluted average share count of approximately 520 million shares driven by increased option exercises in the first quarter. Based on these factors, we now expect 2019 adjusted earnings, excluding special items, of $3.27 to $3.35 per diluted share. This reflects the benefit of our first quarter overachievement as well as the anticipated shift in R&D investments to future quarters.

    就全年而言,我們目前預期調整後有效稅率約為17%,反映第一季的有利因素。由於第一季選擇權行使增加,我們目前預期全年稀釋後加權平均股數將略高,約為5.20億股。基於上述因素,我們目前預期2019年調整後盈餘(不含特殊項目)為每股稀釋盈餘3.27至3.35美元。此反映第一季優於預期的表現,以及預期研發投資將轉移至後續季度。

  • Finally, for the year, we continue to expect to generate operating cash flow of $2.3 billion and free cash flow of $1.6 billion. Specific to the second quarter of 2019, we expect sales to decline approximately 2% on a reported basis, growth of approximately 2% on a constant currency basis and growth of 2% to 3% on an operational basis. And we expect adjusted earnings, excluding special items, of $0.80 to $0.82 per diluted share.

    最後,就全年而言,我們仍預期將產生23億美元的營運現金流,以及16億美元的自由現金流。就2019年第二季而言,我們預期報告口徑銷售約下滑2%,固定匯率成長約2%,營運口徑成長2%至3%。我們並預期調整後盈餘(不含特殊項目)為每股稀釋盈餘0.80至0.82美元。

  • With that, we can now open up the call to Q&A.

    接下來,我們可以開放進入問答環節。

  • Operator

    Operator

  • (Operator Instructions) I would like to remind participants that this call is being recorded, and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com. And our first question comes from Robbie Marcus of JPMorgan.

    (接線員指示) 提醒各位與會者,本次電話會議將被錄音,並將於Baxter International網站提供為期60天的數位重播,網址為www.baxter.com。我們的第一個問題來自摩根大通(JPMorgan)的Robbie Marcus。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • There's obviously a lot of investor focus on Medication Delivery and Nutrition. But we're also seeing some really good results out of pharma. So maybe you could just spend a minute and discuss some of the puts and takes in the quarter in Medication Delivery and what you're seeing, but also some of the offsets and the benefits you're seeing in pharma. And then any commentary you can give us on expected cadence for the balance of the year given the focus there.

    顯然投資人對藥物輸送(Medication Delivery)與營養(Nutrition)有很高的關注度。但我們也看到製藥業務(pharma)有一些非常不錯的成果。所以也許你可以花一點時間談談本季在藥物輸送方面的一些利多與利空(puts and takes)以及你所看到的情況,同時也談談你在製藥業務中看到的一些抵銷因素與好處。另外,鑑於大家對這些領域的關注,你能否就今年剩餘期間的預期節奏(cadence)提供一些評論。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Robbie, I will start, and then I'll pass on to Jay. Well put, investors tend to focus on things that they feel most comfortable which not necessarily is how management feels. So probably this answers about 50 questions that I'm going to get on the same thing that you just asked. So I feel comfortable with our ramp up in Medication Delivery. Why is that? First of all, the first quarter last year, we had close to $50 million in excess purchases in LVPs and SVPs that were not necessarily needed but were purchased because the hurricane effect, the flu that was very hard and people stocking up all those products. Consequently, the other quarters that we had were -- it started with quarter 2 and then culminating with 3 and 4, were really, really destocking, severe destocking. So when I compare Q1 this year with Q1 last year, what I get is a negative growth, rightfully so. Now why do I believe that we can get to the guidance in Medication Delivery? Right now, I have no indication otherwise. First of all, we have a good pipeline of pump either conversions or replacements in the horizon. So we feel good about that. Second, we are, as you know, have signed all the GPO contracts with extension of supply of our LVPs and SVPs. We're now signing IDNs with some of the GPOs with almost 100% of IDNs we signed and with opportunity to continue to gain potential market share because the investment that Baxter made in its supply chain culminating with investment in quality that resulted with the FDA issuing voluntary action indicated from the inspection that they had in December, not necessarily I'm affirming that the FDA will lift or not the warning letter that we have in those 2 facilities but indicates that our efforts have resulted in progress against observations of the past. So when we show this to our customers and potential customers, we have now redundancy in our supply chain, and people should feel comfortable about that, okay? So the SVPs and the LVPs, which are part of Medication Delivery, including the pumps, we have a plan to get there. And right now, I have nothing otherwise telling me that the plan is in jeopardy. Okay. When I shift to Nutrition, Nutrition is a longer recapture of the market. It's a product that has different indications for use. The discretion of the nutritionist and the physician changed once we could not supply them with amino acids after the hurricane. Practice have changed. We see us continue to make progress. It's not a '19 story. It's a '20 story, but I feel comfortable that we have enough gas in the tank with the launch of the Clinolipid this year that we can augment this growth.

    Robbie,我先開始,然後再交給Jay。說得很好,投資人往往會聚焦在他們覺得最熟悉、最有把握的事情上,但這不一定與管理層的看法一致。所以這大概能回答我接下來會被問到、跟你剛才問題相同的約50個問題。因此,我對我們在藥物輸送業務的爬坡(ramp up)感到有信心。為什麼?首先,去年第一季,我們在大容量輸液(LVPs)與小容量輸液(SVPs)上有接近5,000萬美元的超額採購,這些不一定需要,但因颶風效應、流感非常嚴重,以及大家囤貨這些產品而被採購。因此,後續幾個季度——從第二季開始,並在第三、第四季達到高峰——出現了非常、非常明顯的去庫存(destocking),而且是嚴重去庫存。所以當我把今年第一季與去年第一季相比,得到的是負成長,這是合理的。那為什麼我相信我們能達到藥物輸送的指引(guidance)?目前我沒有任何相反的跡象。首先,我們在未來有一個良好的幫浦(pump)管線,包含轉換或汰換。所以我們對此感到樂觀。第二,如你所知,我們已經與所有GPO簽署合約,延長我們LVP與SVP的供應。我們現在也正與部分GPO一起簽署IDN(整合式醫療體系)合約;我們已簽下的IDN幾乎達到100%,並且有機會持續提升潛在市占,因為Baxter在供應鏈上的投資——最終也體現在品質投資上——使得FDA在12月的稽查後,出具了「自願性行動指示」(voluntary action indicated);這並不代表我在確認FDA一定會或不會撤銷我們在那兩座廠的警告信(warning letter),但它顯示我們的努力已在改善過去的觀察缺失方面取得進展。因此,當我們把這些展示給現有客戶與潛在客戶時,我們的供應鏈現在具備備援(redundancy),大家應該會對此感到放心,好嗎?所以SVP與LVP——它們是藥物輸送的一部分,包含幫浦——我們有一個達標計畫。而目前沒有任何訊息顯示這個計畫正面臨風險。好。當我轉到營養業務時,營養的市場收復(recapture)需要更長時間。這是一個在使用適應症(indications for use)上較為多元的產品。在颶風之後,由於我們無法供應胺基酸,營養師與醫師的裁量與選擇發生了改變。臨床實務已經改變。我們看到自己持續取得進展。這不是2019年的故事。這是2020年的故事,但我有信心,隨著今年Clinolipid的上市,我們「油箱裡還有足夠的油」(有足夠動能)來推升這個成長。

  • Let me shift now to the Pharmaceutical business. When I first came to Baxter, I thought Baxter had a hidden gem in its ability to mix APIs in solution, make them stable either at room temperature or frozen and continue to advance in this niche space that has been very good to Baxter. Our Pharmaceutical team has executed extremely well, not only on new molecules that we're launching but also in molecules that we purchased through Claris. So we will continue to double that in Pharmaceuticals. We don't tell everything to everyone that we're doing, but we have a significant amount of development, a very healthy pipeline in Pharmaceutical, and that was by design put in play to create diversification for Baxter's base business, and what it's doing today is exactly that. I feel very comfortable about Acute Therapies. I think we are -- huge pluses from last year. I see that business growing. We have an opportunity with this business to get close to double digits even in face of a tough comp from last year's first quarter flu season. We launched PrisMAX. We just got file with the FDA, and the FDA started its period of review of our PrisMAX in U.S. It's doing well outside the U.S. Prismaflex, which is the generation before that, just got augmented with 2-way communication to the EMR. I found also Advanced Surgery to be doing a pretty good job in getting market share. We are there. There is a shortage in the market due to a competitor having a recall. We have capacity. Our FLOSEAL is still the best product out there for severe bleeding. So we're still doing well. We took the business from Mallinckrodt, RECOTHROM and PREVELEAK and did extremely well last year with it. So I find the execution of the company going well.

    我現在轉到製藥業務。我剛加入Baxter時,我認為Baxter在將API(活性藥物成分)混合於溶液中、使其在室溫或冷凍條件下保持穩定,並持續在這個利基領域推進的能力上,擁有一顆被低估的寶石,而這個領域一直以來對Baxter非常有利。我們的製藥團隊執行得非常出色,不僅是在我們正在推出的新分子(new molecules)上,也包括我們透過Claris收購而來的分子。因此,我們會在製藥業務上持續加倍投入與擴張。我們不會把我們正在做的每件事都對所有人公開,但我們有相當可觀的開發量、非常健康的製藥管線;這是刻意規劃、用來為Baxter的基礎業務創造多元化,而它今天所發揮的作用正是如此。我對急性治療(Acute Therapies)非常有信心。我認為我們——相較去年有非常大的正面改善。我看到這個業務在成長。即使面對去年第一季流感季帶來的艱難比較基期(tough comp),我們仍有機會讓這個業務接近雙位數成長。我們推出了PrisMAX。我們剛向FDA遞交申請(file),FDA也已開始對我們在美國的PrisMAX進行審查期(period of review)。它在美國以外的市場表現良好。Prismaflex(上一代產品)也剛新增了與EMR(電子病歷)雙向通訊的功能。我也看到先進外科(Advanced Surgery)在取得市占方面做得相當不錯。我們已經就位。由於競爭對手發生召回(recall),市場上出現短缺。我們有產能。我們的FLOSEAL仍然是市場上針對嚴重出血最好的產品。所以我們仍然表現良好。我們從Mallinckrodt接手了RECOTHROM與PREVELEAK業務,去年在這方面做得非常出色。因此我認為公司整體的執行狀況良好。

  • So going back to Medication Delivery, what I have in front of me is no indication that we're not going to do what we said we are going to do. So perhaps this can alleviate the same question in 5 different versions that may come after you. And one last comment is on Renal Care. Our patient growth has been good. It has been slightly over 5%. U.S. is doing extremely well with 8.5% growth in peritoneal dialysis patient growth. So we feel good about that. We got out on purpose of bloodlines. We made no money on that business. That business was $40 million, $50 million that was making no profit. As a matter of fact, we're losing money. So we made the right decision there. So all in all, I think the company is focused on execution, and we are absolutely with a brand-new team in the U.S. led by [Josette Macauley] and by Heather Knight, both of them with great track records, we continue to strive to meet our commitments.

    回到藥物輸送,我目前看到的情況是,沒有任何跡象顯示我們無法做到我們說要做到的事。所以也許這能減少之後可能出現、只是換了5種不同問法的同一個問題。最後再補充一點關於腎臟照護(Renal Care)。我們的病患成長表現不錯。略高於5%。美國表現非常好,腹膜透析(peritoneal dialysis)病患成長達8.5%。所以我們對此感到樂觀。我們是有意退出血路管(bloodlines)業務的。那個業務我們賺不到錢。那個業務規模約4,000萬到5,000萬美元,但沒有任何利潤。事實上,我們是在虧錢。所以我們做了正確的決定。總體而言,我認為公司聚焦在執行力;而且在美國由一個全新的團隊領導——由[Josette Macauley]與Heather Knight帶領,兩位都有很好的過往績效——我們會持續努力達成我們的承諾。

  • Robert Justin Marcus - Analyst

    Robert Justin Marcus - Analyst

  • That's great color, Joe. Maybe Jay, just one quick question. We saw R&D tick down a little bit and SG&A tick up a little bit in the quarter, but you felt confident enough to raise the bottom end of the operating margin guidance for the year. Maybe just give us a little color in what was postponed in R&D and what the investments are in SG&A.

    這個說明很有幫助,Joe。也許 Jay,我就一個簡短問題。我們看到本季研發費用略有下降、SG&A 略有上升,但你們仍有信心把全年營業利益率指引的下緣上調。能否請你多補充一些:研發有哪些項目被延後,以及 SG&A 的投資主要投在哪些方面?

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Sure. So as I referenced during the call, one of the things we are incredibly excited about is the new product pipeline that we have. We're launching probably more products this year than we have in many years. But attendant with that, we want to make sure that we have the right commercial teams and commercial investments on the ground to support successful launches. So this was a rare quarter. On the face of it, SG&A grew 0%. But on a constant currency basis, we did see a few points of growth adjusting for TSAs, maybe it's 3% growth. And really what it comes down to is some of those select marketing investments. I'll stop short of delineating actually where those investments took place. But from an investment standpoint again, we just want to make sure that the markets are ready to successfully launch. Now from an R&D standpoint, it's always difficult to get the exact timing of specific milestone payments outlined in a quarterly plan. And so one of the things we found as we looked at results for this year is certain of our payments were shifting from Q1 to future quarters. And so we expect an acceleration as we move through Q2 to Q4 in terms of some of these payments. And frankly, we have reflected in our guidance roughly a $0.03 shift of R&D spending from Q1 to later quarters. It's not specific to one program. And I think from my standpoint, most importantly, it does not impact the launch timings of any of the products that we put forth. So there's no change to time lines. We can talk more about it but we are as bullish as we've ever been about the pipeline, but we did see some phasing. And we did not want to reduce R&D spending on a full year basis. We're going to see that spending come through in future quarters. The only other comment I would make is one of the things we've been really focused on is improving the efficiency of our R&D spending. So there have been a number of global initiatives in terms of consolidation and simplification, and you are seeing some of that yield dividends in the overall performance of the spend category.

    當然。如同我在電話會議中提到的,我們非常振奮的一點是我們擁有全新的產品管線。我們今年推出的產品數量,可能會是多年來最多的一次。但與此同時,我們也希望確保在各市場端具備正確的商業團隊與商業投資,以支援成功上市。所以這是一個相對少見的季度。表面上看,SG&A 成長為 0%。但以固定匯率口徑來看,若調整 TSA 的影響,我們確實看到成長了幾個百分點,可能約 3% 的成長。歸根結底,主要來自部分精選的行銷投資。我先不具體細分這些投資究竟發生在哪些地方。但從投資角度來看,我們只是想確保各市場已準備就緒,能夠成功推動上市。至於研發方面,要在季度計畫中精準掌握特定里程碑付款的確切時點一直都不容易。因此,我們在檢視今年的結果時發現,部分付款從 Q1 轉移到後續季度。所以我們預期在 Q2 到 Q4 期間,這些付款會加速發生。坦白說,我們已在指引中反映了研發支出約 $0.03 從 Q1 轉移到後續季度的變動。這並非針對單一專案。而且我認為最重要的是,這不會影響我們所提出任何產品的上市時程。所以時間表沒有改變。我們可以再多談一些,但我們對管線的看法依然一如既往地樂觀,只是確實看到一些費用時點的分期。我們並不想在全年口徑下削減研發支出。我們會在未來幾個季度看到這些支出發生。我唯一想補充的是,我們一直非常專注於提升研發支出的效率。因此在整併與簡化方面推動了多項全球性措施,而你也正在看到這些措施在整體支出類別的表現上開始帶來成效。

  • Operator

    Operator

  • And our next question comes from Bob Hopkins of Bank of America Merrill Lynch.

    下一個問題來自美國銀行美林(Bank of America Merrill Lynch)的 Bob Hopkins。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • Just to follow up on that last train of thought on the pipeline, Jay or Joe. Could you just talk a little bit about key pipeline time lines or launch dates for the rest of this year? Just kind of refocus us on what you think are the most important things as we look forward over the next 6 to 12 months on the pipeline perspective? And how that drives your confidence, not only in the outlook for this year but in the outlook for acceleration for next year as you'd expressed in the LRP.

    想延續剛才關於產品管線的那個思路,Jay 或 Joe。能否請你們談一下今年剩餘時間的關鍵管線時程或上市日期?也就是說,從管線角度看,未來 6 到 12 個月你們認為最重要的事項是什麼,請幫我們重新聚焦一下。以及這如何驅動你們的信心,不僅是對今年展望,也包括你們在 LRP 中所提到的明年加速成長的展望?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Bob, let's start with Pharmaceutical as we have a couple of molecules that we're launching. We are expecting a good-sized molecule for sometime early next year. So we're talking about 6 to 12 months from today. We also have the version 9 of our pump we launched last year, but we have a new pump platform coming up next year. And we're going to have 2 pumps coming out right out of the gate, which is a large volume pump and syringe pump, all integrated 2-way integration with EMR, all the stuff that you should have plus the best drug library in the market. We will have later that year, which is next year, we'll have the PCA pump, which is the third leg of the stool. And then in another 6 months after that, we'll have the ambulatory pump. So we have a 4-pump platform. We also continue to experience a significant uptake in demand for our KAGUYA cycler in Japan. That is going -- it's doing well. We just crossed 1,000-patient mark. And we've seen this business for the first time since I got here with growth in Japan. We also have PrisMAX, which I just spoke about. PrisMAX for the U.S. is a big deal. We hope to get approval probably within 6 months to 8 months, depends upon the FDA review time frame. And so we have over 20 products actually coming up for launch in the next 12 months. So some are small, some are more relevant, some are more long term, some more durable like the pumps and PrisMAX. We continue to look at a lot of different molecules, and so we feel comfortable that Baxter's shifting a bit now from its operations excellence and efficiency as all of you know, we've been doing for the last 3.5 years to start to see the fruits of the innovation coming through.

    Bob,我們先從製藥(Pharmaceutical)開始,因為我們有幾個分子即將上市。我們預期在明年年初左右會有一個規模不小的分子上市。也就是從今天起算約 6 到 12 個月。另外,我們去年推出了第 9 代幫浦,但明年會推出新的幫浦平台。而且一開始就會推出兩款幫浦:大容量幫浦與注射器幫浦,皆具備與 EMR 的雙向整合,以及你應該具備的所有功能,並搭配市場上最佳的藥物資料庫。同年稍晚,也就是明年,我們會推出 PCA 幫浦,這是三足鼎立的第三支柱。再過另外 6 個月,我們會推出攜帶式(ambulatory)幫浦。因此我們將形成一個四款幫浦的平台。我們也持續看到日本市場對我們 KAGUYA cycler 的需求顯著提升。這項產品表現良好。我們剛剛跨越 1,000 名病患的里程碑。而且自從我來到這裡以來,我們第一次看到日本業務出現成長。我們還有 PrisMAX,我剛才也提到過。PrisMAX 對美國市場而言非常重要。我們希望能在大約 6 到 8 個月內取得核准,具體取決於 FDA 的審查時程。因此,未來 12 個月內實際上會有超過 20 項產品準備上市。其中有些較小,有些更具關聯性;有些偏長期,有些更具持久性,例如幫浦與 PrisMAX。我們也持續評估許多不同的分子,因此我們很有信心,Baxter 現在正從各位所熟知、過去 3.5 年一直在做的營運卓越與效率提升,逐步轉向開始看到創新成果的落地。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • And then just one quick follow-up for Jay. Jay, can you just comment on the puts and takes impacting the gross margin this quarter? It was a little weaker than we anticipated, and then your expectations for how gross margin flows over the course of the rest of the year.

    另外再快速追問 Jay 一題。Jay,你能否評論一下本季影響毛利率的正負因素?毛利率比我們預期稍弱,以及你對今年剩餘期間毛利率走勢的看法。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Yes. So from a gross margin standpoint, that was principally in line with my expectations, in large part because of the significant headwinds we experienced in some high-margin products in the first quarter. And so if you look at the first half of the year, we have a big drag related to BREVIBLOC. It's basically $30 million plus in Q1. It's another $30 million in Q2, and that comes through at a much higher margin than the corporate average. Furthermore, we have a little bit of an FX headwind in the quarter. We also have a cyclo headwind year-over-year again in the first quarter. And so those were particularly pronounced year-over-year headwinds that impacted the first quarter. As we move to the balance of the year, we'll see the normal cadence of improving gross margins throughout the year. So typically, Q4 is our strongest gross margin quarter. Q1 is typically our lightest. So we'll see that uptake as we normally do. But then we'll also have the benefit of an accelerated sales growth in the second half of the year, which will lend itself to a higher gross margin, both from a mix standpoint but also from a utilization in our manufacturing facility standpoint. If you look at the first half of the year, our overall guidance operationally is in the 2% to 3% range. As we move to the back half of the year based on easier comps but other accelerations as well, you start to see a much faster sales growth and an uptick in overall sales. So I think those are a few of the drivers that impacts gross margin. But like I said, this is largely in line with my expectations.

    是的。就毛利率而言,基本上與我的預期一致,主要原因是我們在第一季於部分高毛利產品上遭遇了顯著逆風。因此如果你看上半年,我們會看到與 BREVIBLOC 相關的一個很大的拖累。Q1 基本上是超過 3,000 萬美元。Q2 也會是 3,000 萬美元,而這項產品的毛利率遠高於公司平均。此外,本季還有一些匯率(FX)逆風。同時,第一季也再次出現 cyclo 的年對年逆風。因此,這些都是特別明顯的年對年逆風,影響了第一季。隨著我們進入今年剩餘期間,我們會看到毛利率在全年逐步改善的正常節奏。通常 Q4 是我們毛利率最強的一季。Q1 通常是最弱的一季。所以我們會像往常一樣看到毛利率回升。此外,我們也會受惠於下半年銷售成長加速,這將推升毛利率:一方面來自產品組合(mix),另一方面也來自製造設施產能利用率提升。如果你看上半年,我們在營運口徑下的整體指引約在 2% 到 3% 的區間。進入下半年,基於較容易的比較基期以及其他加速因素,你會看到更快的銷售成長與整體銷售的上升。我認為這些就是影響毛利率的幾個驅動因素。但如我所說,整體而言這大致符合我的預期。

  • Operator

    Operator

  • And our next question comes from David Lewis of Morgan Stanley.

    我們的下一個問題來自摩根士丹利(Morgan Stanley)的 David Lewis。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Just 2 quick questions for me. The first is just want to focus on cash flow and capital deployment. Maybe Jay, the question for you would be cash flow got up to a slower start here in the first quarter. So what's the pacing? What drove that in the first quarter? What's the pacing for the balance of the year? And then related to that, Joe, I just wonder if you could take a second and talk about cap deployment. Obviously, you're still continuing to purchase huge dramatic amounts of stock, I think $600 million this quarter. What are you thinking in terms of the pace of capital deployment relative to buyback versus M&A the balance of the year, and I had one quick follow-up.

    我這邊只有兩個簡短問題。第一個想聚焦在現金流與資本配置。也許 Jay,想請教你的是,第一季現金流的起步似乎比較慢。所以節奏是怎麼樣?第一季是什麼因素驅動了這個情況?今年剩餘期間的節奏如何?另外與此相關,Joe,我想請你花點時間談談資本配置。顯然你們仍在持續回購相當大量的股票,我想本季大約是 6 億美元。就今年剩餘期間而言,你們如何看待資本配置的節奏:回購相對於併購(M&A)各自的比重與步調?我還有一個簡短的追問。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Sure. As it relates to cash flow, the cash flow came in, in line with our expectations. Q1 is typically the lowest quarter of the year for a number of different reasons, one of which is incentive payout from the prior year occurs once a year in the first quarter. We also had a large vendor payment that we had anticipated in the first quarter of this year that impacted the number. So, by and large, it came in very close to our expectations. So what that implies, David, to your point is a significant ramp as we approach the back portion of the year, and we'll start to see improvements in Q2. Now looking at the balance sheet -- and so what will happen, what will drive this improvement is operating margin and earnings growth, of course. But then you transition to look at working capital. And on the working capital side, 2 categories we don't expect to change too much: our days payable for the first quarter will be in the mid-50s, our days receivable will be in the low to mid-50s. So those 2 categories are exactly where we want them to be, and we'll continue to manage those aggressively. Where we expect to see a significant improvement in working capital relates to inventory. This is an area that has disappointed us over the last year. The inventory buildup as a result of different sales mix than we anticipated has been a real problem and something that we focused on correcting. But it's not something that corrects overnight. And in the first quarter of the year, the days inventory on hand will end at roughly 107 days. By year-end, we'll expect to see roughly a 10-day improvement in that particular area. And frankly, that will be the drive the lion's share of performance in our cash flow, free cash flow for the year. We've got a new leader in supply chain, Philippe Reale comes to us, and we're excited to have him on Board. He's been on Board for several months, and he has a number of new operating mechanisms. Joe and I are personally involved as well along with our Head of Operations. So we feel quite good about this, and we also knew that this number would be high in Q1. But I definitely am very focused on watching this improve through the balance of the year. Joe, do you want to take the question on capital deployment?

    好的。就現金流而言,實際現金流與我們的預期一致。第一季通常是一年中現金流最低的季度,原因有好幾個,其中之一是前一年度的激勵獎金發放每年一次,會在第一季支付。我們在今年第一季也有一筆原本就預期會發生的大額供應商付款,影響了該數字。因此整體而言,結果非常接近我們的預期。所以 David,正如你所說,這意味著當我們接近下半年時,現金流會顯著加速,我們也會在第二季開始看到改善。再看資產負債表——推動這項改善的,當然是營業利益率與獲利成長。接著再轉到營運資金。在營運資金方面,有兩個類別我們預期不會有太大變化:第一季的應付帳款天數會在 50 多天的中段,應收帳款天數會在 50 多天的低到中段。所以這兩個類別正好在我們希望的位置,我們也會持續積極管理。我們預期營運資金會有顯著改善的部分在於存貨。這是過去一年讓我們失望的領域。由於實際銷售組合與我們原先預期不同而造成的存貨累積,一直是個真正的問題,也是我們專注要修正的事項。但這不是一夕之間就能修正的。而在今年第一季,存貨在手天數(days inventory on hand)大約會落在 107 天左右。到年底,我們預期在這個領域大約能改善 10 天。坦白說,這將會驅動我們今年現金流、自由現金流表現中的最大部分。我們在供應鏈方面有一位新的領導者 Philippe Reale 加入,我們很高興他加入團隊。他已經在團隊中幾個月了,也帶來了多項新的營運機制。Joe 和我也會親自參與,並與我們的營運主管一起投入。所以我們對此相當有信心,而且我們也知道第一季這個數字會偏高。但我確實非常專注於觀察它在今年剩餘期間持續改善。Joe,你要不要回答關於資本配置的問題?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Yes, just going back into inventory. A bit of the inventory was planned because we had nothing in terms of large volume parenterals in the inventory. Now we carry inventory at the levels that are appropriate to service our customers of today and future customers. So going back to capital deployment, David, we continue to look extensively at all kinds of different opportunities. We like some of the stuff that we're seeing. We're looking at molecules. We buy molecules, we buy small stuff all the way to large stuff we're looking at. Buying shares back until very recently was a good deal because we thought the multiple was depressed, and our treasury group did a great job. We continue to evaluate the deployment of capital in face of opportunities that we have in front of us. So we may or may not continue with the program at the pace that we had in the first quarter. It will depend a lot upon what opportunities we have in M&A. As I said before, there's always a good balance between strategy and buying shares back. We couldn't pass the opportunity in the last 6 months to buy the shares because we thought the price was adequate. And lo and behold, I think we made a very good decision in buying that. And if we speak to our investors, folks who are long holders of Baxter, they probably appreciated the fact that we had an opportunity, took that opportunity. Nothing would payback as best as that did for us and for our investors. But with that said, we need to continue to look at expanding Baxter's technology and opportunities. There's not a week that goes by that I don't see 1 or 2 opportunities. And as I say to folks, when it's the right one, you'll be the first one to know.

    好的,先回到存貨。有一部分存貨是計畫性的,因為我們在大宗注射劑(large volume parenterals)的存貨方面原本幾乎沒有庫存。現在我們把存貨維持在適當水位,以服務我們目前的客戶以及未來的客戶。再回到資本配置,David,我們持續廣泛評估各式各樣的機會。我們喜歡目前看到的一些標的。我們在看分子(molecules)。我們會買分子,也會買小型案子,乃至於大型案子,我們都在評估。直到最近為止,回購股票是一筆划算的交易,因為我們認為估值倍數被壓低了,而我們的財務(treasury)團隊做得非常好。面對眼前的機會,我們會持續評估資本的運用。因此,我們可能會、也可能不會以第一季那樣的速度繼續推進該計畫。這在很大程度上取決於我們在併購(M&A)方面有哪些機會。如我先前所說,策略投資與回購股票之間永遠需要取得良好平衡。過去 6 個月我們無法錯過回購的機會,因為我們認為價格合適。結果證明,我認為我們做了非常好的決定。如果我們和投資人、也就是長期持有 Baxter 的投資人交流,他們大概也會欣賞我們有機會就把握住。沒有任何事情能像那樣,為我們以及投資人帶來那麼好的回報。但話說回來,我們仍需要持續尋求擴展 Baxter 的技術與機會。幾乎每週我都會看到 1 到 2 個機會。而我也常跟大家說,當遇到對的那一個,你們會是第一個知道的人。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Okay. And with my follow-up, I take a step back here. If I think about the debate into this year, it really was focused on the ability to drive earnings and your ability to deliver Med Delivery. I think in the first quarter, you jumped over the hardest margin quarter of the year, raising operating guidance and now we see raise earnings, so I think that's sort of asked and answered. Just to come back to Medication Delivery, Joe, I think you did a nice job sort of outlining how from a share capture perspective customer recapture, you're doing as well as you expected. The key question I think it's just from Medication Delivery underlying fundamentals, the demand equation in the channel and where you see inventories in the channel, how comfortable are you that those signals and what you're seeing in the channel are stable at a pace that you can build on and sort of benefit from this recapture you are discussing?

    好的。至於我的追問,我先退一步看。如果我回想今年初市場的討論焦點,主要在於你們推動獲利的能力,以及你們交付藥物輸送(Med Delivery)的能力。我認為在第一季,你們已經跨過一年中毛利率最具挑戰的季度,上調了營運指引,現在我們也看到上調獲利,所以我想這部分算是問了也答了。再回到藥物輸送(Medication Delivery),Joe,我認為你在說明市占取得、客戶回流(customer recapture)方面做得很好,你們的表現也如預期。我認為關鍵問題在於藥物輸送的基本面:通路中的需求狀況,以及你們看到的通路庫存水位;你們對於這些訊號、以及你們在通路中看到的情況是否穩定、有沒有穩定到足以在此基礎上持續推進並從你們所談到的客戶回流中受益,有多大的信心?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • So David, I can see where our investors feel uneasy looking at a performance of the last year, a couple of quarters, coming into the first quarter and said, "How can you get there?" and it's one of the things is our credibility, right? So what we're saying to you is that we can do that because we can see through it, and we have the numbers, we have the reviews, but let me give a little bit more color. The market is quite stable, meaning there are not shortages out there. There's not a company that is out of the market. There's nothing like that. So what is important to our customers? That you have continuity of supply, that you have inventory, that you have the ability to supply a large swath of products under the Medication Delivery and be safe at the end of the day. So what Baxter brings to the table are a few things. We are a very stable supply chain right now. We modified significantly the last 3 years. We invested over $120 million in our factories to improve our quality, to improve output. We completely revamped our management at our factories. So we do have the capacity today from Canada, United States, Brazil, Spain and Ireland. We have a network that is flexible enough that can provide products. We launched a new product that has been very instrumental in recapturing the small-volume parenterals, the Mini-Bag Plus, which is the single pack. We also took advantage of one of the competitors that filled in during the shortage of small-volume parenterals is on a recall, and the product is not available on the market, which brings our product to life as a safe product, Mini-Bag Plus. So we've been seeing, signing 2-, 3-, 4-year agreements with hospital systems right now. So we feel that our pipeline is strong enough of deals that we think we can deliver on our promise. Things can change 6 months down the road. I don't think, as I see it today, that they will. But things can. What we're doing is making sure that we are signing every single account, and we're showing to customers who are not ours today how Baxter can serve them with value as well as supply and breadth of products. Remember, we are a company that goes from the pharmacy all the way to the ICU. So we have a breadth of products that can be offered that way. On top of it, we also have one of the best pumps, if not the best drug library in the market, which is in our SIGMA SPECTRUM version 9. So all of this together with the new team that we have with experienced people, it's not a new team, but it's experienced people, I'm very confident that we can get to the end of the year and deliver to our investors what we said we're going to deliver. If we have any changes to that, we will let you guys know.

    所以,David,我能理解我們的投資人回頭看過去一年、過去幾個季度的表現,進入第一季時會感到不安,並問:「你們怎麼可能做到?」而其中一個關鍵就是我們的可信度,對吧?所以我們要跟你說的是,我們之所以能做到,是因為我們看得很清楚,我們有數據、有審查結果,但我再補充一些細節。市場相當穩定,也就是說外面並沒有短缺。沒有任何一家公司退出市場。沒有那種情況。那對我們的客戶來說,什麼最重要?就是你能夠持續供應、你有庫存、你有能力在「藥物輸送(Medication Delivery)」領域供應很大範圍的產品,並且最終能確保安全。所以 Baxter 能帶到桌面上的有幾件事。我們目前的供應鏈非常穩定。過去 3 年我們做了大幅度的調整。我們在工廠投入超過 1.2 億美元,以提升品質、提高產出。我們也徹底改造了工廠的管理團隊。因此,我們今天確實具備來自加拿大、美國、巴西、西班牙與愛爾蘭的產能。我們有一個足夠靈活的網絡,可以提供產品。我們推出了一款新產品,對於重新奪回小容量注射劑(small-volume parenterals)市場非常關鍵:Mini-Bag Plus,也就是單包裝(single pack)。我們也把握了一個機會:在小容量注射劑短缺期間曾補位的一家競爭對手目前正在召回,其產品在市場上不可得,這讓我們的 Mini-Bag Plus 作為安全產品的價值更加凸顯。因此,我們目前看到並正在與醫院體系簽署 2 年、3 年、4 年期的合約。所以我們認為,我們的交易管線足夠強,我們有信心能兌現我們的承諾。未來 6 個月情況可能會改變。但以我今天看到的情況,我不認為會。不過事情確實可能改變。我們正在做的是確保把每一個客戶都簽下來,並向目前還不是我們客戶的對象展示:Baxter 如何在供應、產品廣度以及價值上為他們服務。記住,我們是一家從藥房一路延伸到 ICU 的公司。所以我們能以這種方式提供廣泛的產品組合。此外,我們也擁有市場上最好的幫浦之一,甚至可以說擁有最好的藥物資料庫(drug library),就在我們的 SIGMA SPECTRUM 第 9 版中。把這些再加上我們這支新團隊——其實不是新手,而是有經驗的人——我非常有信心,我們能走到年底,並向投資人交付我們所承諾要交付的成果。如果這方面有任何變化,我們會讓各位知道。

  • Operator

    Operator

  • And our next question comes from Danielle Antalffy of SVB Leerink.

    下一個問題來自 SVB Leerink 的 Danielle Antalffy。

  • Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst

    Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst

  • Just wanted to ask a question about how to think about the different business segments and their growth profiles specifically in Q2. Last quarter, you guys did a great job, I thought, of calling out some of the quarter-specific headwinds. Can you help us think about how to think about that for Q2? And I guess specifically as it relates to some of the more controversial businesses like Medication Delivery. And then I have one follow-up.

    我想問一個問題:該如何看待不同業務部門在第二季(Q2)的成長輪廓。我覺得上個季度你們做得很好,特別是點出了幾個屬於該季度特有的逆風因素。你們能幫我們理解一下,對 Q2 應該如何看待這些因素嗎?我想特別是與一些較具爭議的業務(例如藥物輸送 Medication Delivery)相關的部分。然後我還有一個追問。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • Sure. Q1 was interesting, right? Because we had a number of headwinds that were specific to the quarter, and some of those go away, some of those persist in Q2. And so I referenced earlier BREVIBLOC. That was like $33 million in the first quarter. It will be around $30 million in the second quarter. So that is a real headwind to operational pharmaceutical sales growth that we're mindful of. And we have tremendous work coming from this group in terms of all the activity and the new launches but that's going to be a specific headwind for the second quarter. We've talked in the past about the bloodlines headwind, which is on a full year basis around $50 million. We'll see continued decline related to this particular item impacting our renal growth in the second quarter. But there are a couple of headwinds that subside. One is you will see a normalization of the acute growth because the flu headwind of roughly $10 million moves away in the second quarter. So we'll see a solid performance, improved performance out of that group in the second quarter. And then the IV buy-in that we have described in the past, which impacted the first quarter of this year, again subsides. Now interestingly enough, that headwind becomes an actual tailwind in Q3 and Q4 because our Q3 and Q4 were depressed by this amount as Joe referenced earlier. Q2 is fairly neutral. So as we think about the growth profile in Q2, you'll see renal growth kind of consistent with overall annual growth. We expect to see acute growth closer to the annual rate. That should be in line with that. Medication Delivery will increase in the second quarter but not to the extent that we'll see in the back 2 quarters of the year as we look at all of the efforts that Joe described, many of those benefits accrue to the second half of the year. Pharmaceuticals will have a lower rate for the BREVIBLOC reason that I mentioned, and then we should -- we expect to see some Nutrition growth in the quarter as well. Advanced Surgery again should have a solid quarter largely in line with full year expectations, maybe a little bit better. So that really kind of walks you down the overall components of the growth in the second quarter. Like I said, the biggest change in overall growth rate occurs in the second half. So we go from this operational growth of 2% to 3% accelerating to 4% to 5%-ish in the second half of the year.

    當然。第一季(Q1)很有意思,對吧?因為我們有一些只在該季度出現的逆風因素,其中有些在 Q2 會消失,有些則會延續到 Q2。所以我先前提到 BREVIBLOC。第一季大約是 3,300 萬美元。第二季大約會是 3,000 萬美元。所以這對我們的製藥(Pharmaceutical)營運銷售成長確實是一個需要留意的逆風。我們這個團隊在各項活動與新產品上市方面有大量工作在推進,但這仍會是第二季特定的逆風因素。我們過去也談過 bloodlines 的逆風,全年大約是 5,000 萬美元。第二季我們仍會看到與這個特定項目相關的持續下滑,進而影響我們腎臟(renal)業務的成長。不過也有幾個逆風因素會減弱。其中之一是你會看到急性照護(acute)成長的正常化,因為約 1,000 萬美元的流感逆風在第二季消退。因此第二季該團隊會有穩健表現,且表現會改善。另外,我們過去描述過的 IV buy-in(靜脈輸液的提前採購/備貨)在今年第一季造成影響,但在第二季也會消退。有趣的是,到了第三季與第四季,這個逆風會變成實際的順風,因為如同 Joe 先前提到的,我們的 Q3 與 Q4 曾因這個因素而被壓低。第二季則相對中性。所以當我們思考 Q2 的成長輪廓時,你會看到腎臟業務的成長大致與全年整體成長一致。我們預期急性照護的成長會更接近全年成長率。應該會與之相符。藥物輸送(Medication Delivery)在第二季會增加,但幅度不會像今年後兩個季度那麼大;因為就 Joe 所描述的各項努力來看,其中許多效益會在下半年逐步顯現。製藥業務的成長率會因我提到的 BREVIBLOC 原因而較低;此外,我們也預期本季營養(Nutrition)業務會有一些成長。先進外科(Advanced Surgery)同樣應該會有穩健的一季,整體大致符合全年預期,可能還會略好一些。以上大致就是把第二季成長的各個組成因素逐一說明。如我所說,整體成長率最大的變化會出現在下半年。因此,我們會從 2% 到 3% 的營運成長,加速到下半年約 4% 到 5% 左右。

  • Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst

    Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst

  • Okay. That's super helpful, and maybe we can talk about I thought there were 2 really bright spots in the quarter, Pharmaceuticals and the Advanced Surgery business. And I know you called out contract manufacturing. But also curious how much contribution was from new products for pharma and Advanced Surgery because to me, it feels like maybe the pipeline story's really starting to take hold. Any color you could give there would be great.

    好的。這非常有幫助,也許我們可以談談——我覺得本季有兩個非常亮眼的部分:製藥業務以及先進外科業務。我知道你提到了合約製造。但我也好奇,製藥與先進外科的新產品在其中貢獻了多少?因為在我看來,管線的故事似乎真的開始發揮作用了。如果你能提供一些補充說明就太好了。

  • James K. Saccaro - Executive VP & CFO

    James K. Saccaro - Executive VP & CFO

  • We don't really break out new product contribution by quarter, by business. But what I can tell you is in the case of the Pharmaceutical business, we were definitely excited with the launch of dexmedetomidine. That has been well received in the market. It's a novel presentation, and that should be a continued solid growth engine for us for the balance of the year. As we think about BioSurgery, we did have the benefit in our operational growth numbers of the Mallinckrodt assets. Roughly $15 million of RECOTHROM and PREVELEAK featured in our numbers in the quarter. And so that annualizes as a comp moving into the second quarter. So the growth rate will return to a lower rate. But we did see a very solid benefit in the first quarter in particular, in the U.S. As we look forward, BioSurgery has been an area that has been performing well. The team is executing with the core hemostats and sealants, and we're seeing good momentum there. So we'll expect continued positive progress in those areas. And as we think about business development, I do think the assets that we acquired from Mallinckrodt really are a great example of the kind of business development that we can be incredibly successful with. It leverages the same sales call point, same sales team. And we're seeing that really resonate well as we look to commercialize that product.

    我們並不會按季度、按業務別拆分新產品的貢獻。但我可以告訴你的是,就製藥業務而言,我們對右美托咪定(dexmedetomidine)的上市感到非常振奮。市場反應很好。這是一種創新的劑型呈現,預期在今年剩餘期間將持續成為我們穩健的成長引擎。談到 BioSurgery(生物外科),我們的營運成長數字確實受惠於 Mallinckrodt 資產的挹注。本季數字中約有 1,500 萬美元來自 RECOTHROM 與 PREVELEAK。因此,進入第二季後,這部分會年化成為比較基期。所以成長率會回到較低的水準。但我們確實在第一季、尤其是在美國,看到了非常明顯的助益。展望未來,BioSurgery 一直是表現良好的領域。團隊在核心止血劑與封合劑上執行到位,我們也看到良好的動能。因此我們預期這些領域將持續有正向進展。而在業務開發方面,我確實認為我們從 Mallinckrodt 收購的資產,是我們能夠非常成功的業務開發類型的絕佳例子。它運用相同的銷售拜訪點、同一支銷售團隊。而且在我們推動該產品商業化的過程中,我們看到這點確實引起了很好的共鳴。

  • Operator

    Operator

  • And our next question comes from Matt Taylor of UBS.

    下一個問題來自瑞銀(UBS)的 Matt Taylor。

  • Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices

    Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices

  • So the first question I wanted to ask was just on renal market dynamic. So I was wondering if you had seen any shift. It seems like the PD volume are relatively healthy, and I was wondering if you could parse out how much of that you think is coming from cyclers or being helped by the cyclers or if you're seeing any market shift to push patients toward PD.

    我第一個想問的是腎臟市場的動態。我想知道你們是否看到任何變化。看起來 PD(腹膜透析)的量相對健康,我想請你們拆解一下:你們認為其中有多少是來自 cycler(自動腹膜透析機)的帶動或受 cycler 的幫助?或者你們是否看到市場有任何轉變,正在把病人推向 PD?

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Matt, I think what we see is the number of patients are related to penetrate -- a couple of things. One is the penetration of the therapy, our renewed partnership with DaVita and lastly is also maybe related to length of stay in terms of durability of the revenue, right, on therapy. So I would say to the number of patients, I attribute it mainly by the excellent relationship that we have with DaVita where we seek the best therapies for the patients. And the organizations are aligned, and Baxter is making investments in its plants to provide more capacity for growth. In PD right now, as we speak, we're investing dozens of millions of dollars in our facilities to be able to support DaVita. We had this agreement with them. So I find this to be the result of that execution.

    Matt,我認為我們看到的病人人數與滲透率——有幾個因素相關。第一是治療方式的滲透率;第二是我們與 DaVita 重新建立的合作關係;最後也可能與治療持續時間(length of stay)有關,也就是在治療上的留存度,進而影響營收的耐久性。所以就病人人數而言,我主要將其歸因於我們與 DaVita 的卓越合作關係,我們共同為病人尋求最佳治療。雙方組織目標一致,而 Baxter 也正在投資其工廠,以提供更多產能來支持成長。就 PD 而言,此刻我們正在我們的設施投入數千萬美元,以便能夠支援 DaVita。我們與他們有這項協議。因此我認為這是執行落地所帶來的成果。

  • Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices

    Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices

  • Okay. And then I just want to get the 50th question here on delivery. I just wanted to understand the dynamic a little bit better. You called out $50 million of excess purchasing that you had in Q1 '18 and from the outside in it's hard for us to think about the pace of destocking. Could you offer any specific on the next couple of quarters to help us model how the comps are going to play into your recapture in that sector?

    好的。接著我想再問一個關於輸注(delivery)的問題——這大概是第 50 個了。我只是想更了解一下其中的動態。你提到 2018 年第一季有 5,000 萬美元的超額採購,從外部來看,我們很難判斷去庫存(destocking)的速度。你能否就接下來幾季提供一些更具體的資訊,幫助我們建模比較基期將如何影響你們在該領域的回補(recapture)?

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • So Matt, it's $15 million, 1-5 was the stocking impact for U.S. LVPs in the first quarter of last year. We did see some elevated purchases in the first couple of months of the second quarter. And then in June of last year is when we started to see the destocking that occurred throughout the rest of the year. So that's really how it relates to the progression of the destocking impacts for the U.S. LVPs. And again, as Joe was saying, with respect to small-volume parenterals, we are on track with that. Those will continue to ramp throughout the year as well. So our recapture efforts are going there. We're doing really well with our Mini-Bag Plus, particularly the single packs. So we'll continue to drive those efforts, really focused on education about the safety and efficiency of using Mini-Bag Plus to reconstitute drug. So our sales reps are armed with that and are out there working with clinicians on that. I think Joe talked about pump. So continue to see both Spectrum IQ and Evo IQ as well ramp throughout the rest of the year. And in addition, our reallocation of volume to international markets will continue to pick up over the course of the year as well. So I think those are the dynamics. Again, it's more the growth will be more back-end weighted as we face those easier comps with respect to destocking in the U.S. LVP market.

    Matt,是 1,500 萬美元;去年第一季美國 LVP(大容量注射液)的備貨影響是 1,500 萬美元。我們確實在第二季前兩個月看到一些偏高的採購。而去年 6 月開始,我們看到去庫存的情況,並在全年剩餘期間持續發生。所以這就是美國 LVP 去庫存影響的演進節奏。另外,如同 Joe 所說,關於小容量注射劑(small-volume parenterals),我們也在按計畫推進。這些也會在全年持續爬坡。因此我們的回補工作正朝那個方向進行。我們的 Mini-Bag Plus 表現非常好,尤其是單包裝(single packs)。所以我們會持續推動這些工作,重點放在教育市場:使用 Mini-Bag Plus 進行藥品復溶在安全性與效率上的優勢。因此我們的業務代表已具備這些資訊,並在外與臨床人員合作推廣。我想 Joe 也談到了幫浦。所以我們也會持續看到 Spectrum IQ 與 Evo IQ 在今年剩餘期間逐步放量。此外,我們將部分量重新分配到國際市場的作法,也會在今年過程中持續加速。我認為這些就是主要動態。再說一次,當我們面對美國 LVP 市場去庫存所帶來的較容易比較基期時,成長會更偏向下半年。

  • Operator

    Operator

  • And our final question comes from the line of Matt Miksic with Credit Suisse.

    最後一個問題來自瑞士信貸(Credit Suisse)的 Matt Miksic。

  • Matthew Stephan Miksic - Senior Research Analyst

    Matthew Stephan Miksic - Senior Research Analyst

  • I'll spare you the umpteenth Med Delivery question and just ask if you could maybe elaborate on a couple of the other businesses. The first on the PD side. If you could talk, maybe just remind us, what some of the drivers are of that growth, if there's any macro or economic or reimbursement dynamics that are driving that strength in PD. And then I have one follow-up on pharma.

    我就不再問第 N 個醫療輸注(Med Delivery)問題了,改請你們談談其他幾個業務。第一個是 PD。你能否談談、也許提醒我們一下,這項成長的驅動因素有哪些?是否有任何總體、經濟或給付(reimbursement)方面的動態在推動 PD 的強勁表現?然後我還有一個關於製藥的追問。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Matt, the government announcement that they would initiate a move to take patients from clinics to home is too new to have caused any significant impact on our numbers. Our numbers, as I said, are driven primarily in the U.S. by a strong relationship with DaVita. That continues to get stronger. Our availability of product, which is most importantly we are making investments in our plants to supply the market with product. So we will have availability of products for the longer term. We are investing in technology, point of care, for instance, our first patient just came off successfully from the 3-month clinical trial period. We continue to enroll more patients on that technology. So all in all, the U.S. has done well because our renewed effort in partnership. When I look in Asia Pacific, the growth in patients for the year was 6.5%. Don't forget the Asia Pac, primarily China, we are 70-plus percent market share holder in China. And in China, we have twice as many patients in PD that we have in the U.S. And then the areas that we need to continue to improve is Europe has always been behind in PD penetration compared to the U.S. and parts of Asia. So all in all, 5.1% growth in patients for PD is a pretty healthy number. And consequently, now our outlook for the year is a little more than that. So we continue to see a very strong outlook in the U.S., Asia Pacific as well as Canada.

    Matt,政府宣布將啟動把病人從診所轉到居家治療的措施,這消息還太新,尚不足以對我們的數字造成任何顯著影響。如我所說,我們的數字主要在美國是由與 DaVita 的強勁合作關係所驅動。而且這個關係持續在強化。另外還有我們的產品供應能力——最重要的是,我們正在投資我們的工廠,以供應市場所需的產品。因此我們將能在更長期提供產品供應。我們也在投資技術、例如床邊照護(point of care);舉例來說,我們的第一位病人剛成功完成為期三個月的臨床試驗期並退出。我們持續讓更多病人納入使用這項技術。總體而言,美國表現良好是因為我們重新投入的合作夥伴關係努力。再看亞太地區,今年病人數成長為 6.5%。別忘了亞太、主要是中國,我們在中國的市占率超過 70%。而在中國,PD 病人數是美國的兩倍。接下來我們需要持續改善的領域是歐洲:相較於美國與亞洲部分地區,歐洲的 PD 滲透率一直較落後。因此整體而言,PD 病人數 5.1% 的成長是相當健康的數字。也因此,我們目前對全年展望略高於這個水準。所以我們持續看好美國、亞太以及加拿大的前景都非常強勁。

  • Matthew Stephan Miksic - Senior Research Analyst

    Matthew Stephan Miksic - Senior Research Analyst

  • That's great. I appreciate that. And then just on pharma, again impressive growth. Can you talk a little bit about -- maybe remind us or update us as to the kinds of additional assets, businesses, size of these molecules, strategy there and how it compares to sort of the traditional specialty injectable businesses as folks may know it? Just some perspective would be helpful.

    太好了。我很感謝。另外談到製藥業務,再次展現了令人印象深刻的成長。您能否稍微談一下——也許提醒我們或更新一下——關於新增資產、業務的類型、這些分子的規模、相關策略,以及它與大家可能熟悉的傳統專科注射劑業務相比如何?提供一些觀點會很有幫助。

  • José E. Almeida - Chairman, President & CEO

    José E. Almeida - Chairman, President & CEO

  • Yes. So if you compare like BREVIBLOC and cyclophosphamide, we will not see drugs like that in our portfolio, not to that extent anymore because those were drugs that were semi-specialty drugs. They had patents, and they had things that we had, and it was a different Baxter at that time. Our intent in Pharmaceuticals is to launch 3 to 4 molecules a year, which are injectable, mostly, mostly premixes, which is Baxter's strength. It's premix. It's our GALAXY technology that comes to light. We will launch some APIs primarily once we get the warning letter resolved out of Ahmedabad. There will be some APIs launched out of that facility. But if you look at our objective is to launch in 5 areas of care: Oncology, Anesthesia, Antibiotics, Specialty Antibiotics and a conglomerate of small parts of therapy as well as the premixes. So we're going to take those areas of therapy and launch specialty products, 3 to 4 molecules a year. Some are going to be $70 million, $80 million. Some are going to be $3 million, $4 million. It's going to be a mix of them. Our objective by 2023 is to more than double the number of molecules that we currently have, and we are ahead of plan to get there.

    好的。如果拿 BREVIBLOC 和 cyclophosphamide(環磷醯胺)來比較,我們的產品組合中將不會再看到那樣的藥物——至少不會到那種程度——因為那些屬於半專科藥物。它們有專利,也有我們當時所具備的一些條件,而那時的 Baxter 也不同於現在。我們在製藥業務的目標是每年推出 3 到 4 個分子,主要是注射劑,且多數為預混製劑,這是 Baxter 的強項。就是預混。這也讓我們的 GALAXY 技術得以發揮。一旦我們解決 Ahmedabad 廠的警告信問題,我們將主要推出一些 API(原料藥)。該廠將會推出一些 API。但如果看我們的目標,是在 5 個照護領域推出產品:腫瘤、麻醉、抗生素、專科抗生素,以及一些較小治療領域的組合,並包含預混製劑。因此,我們會聚焦這些治療領域,推出專科產品,每年 3 到 4 個分子。有些會是 7,000 萬、8,000 萬美元規模。有些會是 300 萬、400 萬美元規模。會是多元組合。我們到 2023 年的目標,是將目前的分子數量增加到超過兩倍,而且我們目前進度超前,將可達成。

  • Operator

    Operator

  • And that concludes our question-and-answer session. Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating. And everyone, have a great day.

    以上結束我們的問答環節。各位女士、先生,Baxter International 今日的電話會議到此結束。感謝各位參與。也祝各位有美好的一天。